Filing Details
- Accession Number:
- 0001567619-21-008429
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-21 19:59:56
- Reporting Period:
- 2021-04-20
- Accepted Time:
- 2021-04-21 19:59:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1704292 | Zai Lab Ltd | ZLAB | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1835824 | Harald Reinhart | C/O Zai Lab Limited 4560 Jinke Road, Bldg 1, 4Th Floor Pudong, Shanghai F4 201210 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2021-04-20 | 8,000 | $20.90 | 8,000 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2021-04-20 | 8,000 | $150.20 | 0 | No | 4 | S | Direct | |
Ordinary Shares | Acquisiton | 2021-04-21 | 8,000 | $20.90 | 8,000 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2021-04-21 | 8,000 | $161.99 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Stock Options (Right to Buy) | Disposition | 2021-04-20 | 8,000 | $0.00 | 8,000 | $20.90 |
Ordinary Shares | Stock Options (Right to Buy) | Disposition | 2021-04-21 | 8,000 | $0.00 | 8,000 | $20.90 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
92,000 | 2028-03-28 | No | 4 | M | Direct | |
84,000 | 2028-03-28 | No | 4 | M | Direct |
Footnotes
- The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
- The options vest in equal annual installments over five years beginning on 03/28/2019, the first anniversary of the date of grant.